Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL400214 | 0.92 | MBTD1 (0.49) | L3MBTL3L3MBTL1MBTD1HDAC1HDAC6 | |
| SCHEMBL1195043 | 0.90 | HDAC6 (0.59) | HDAC1HDAC6HDAC8MCHR1HRH3 | |
| SCHEMBL10286676 | 0.90 | HDAC6 (0.59) | HDAC1HDAC6HDAC8MCHR1HRH3 | |
| SCHEMBL1109419 | 0.89 | HDAC6 (0.60) | HDAC1HDAC6HDAC8MCHR1HRH3 | |
| SCHEMBL1109307 | 0.84 | MBTD1 (0.51) | L3MBTL3L3MBTL1MBTD1HDAC1HDAC6 | |
| SCHEMBL1109435 | 0.83 | MCHR1 (0.54) | HDAC1HDAC6HDAC8MCHR1DRD2 | |
| SCHEMBL1109236 | 0.82 | HDAC1 (0.53) | HDAC1HDAC6HDAC8HRH3HDAC3 | |
| SCHEMBL1109521 | 0.82 | HDAC6 (0.62) | HDAC1HDAC6HDAC8MCHR1HDAC3 | |
| SCHEMBL10285921 | 0.81 | DRD2 (0.57) | MCHR1CYP2D6CHRM1HTR2ADRD2 | |
| SCHEMBL1912230 | 0.81 | DRD2 (0.57) | MCHR1CYP2D6CHRM1HTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | L3MBTL3 3609/4885L3MBTL1 2665/4885MBTD1 3881/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | L3MBTL3 3609/4885L3MBTL1 2665/4885MBTD1 3881/4885 |
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | L3MBTL3 3609/4885L3MBTL1 2665/4885MBTD1 3881/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | L3MBTL3 3609/4885L3MBTL1 2665/4885MBTD1 3881/4885 |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | L3MBTL3 3609/4885L3MBTL1 2665/4885MBTD1 3881/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | L3MBTL3 3609/4885L3MBTL1 2665/4885MBTD1 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.